Growth Hormone Deficiency Clinical Trial
Official title:
A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers
Verified date | May 2013 |
Source | Aileron Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
Status | Completed |
Enrollment | 33 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 20 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Healthy male or female subjects aged 20 to 50 years, inclusive, at the time of informed consent. 2. Subjects must be in good health as determined by the Investigator based on detailed medical history, physical examination, vital signs, clinical laboratory tests, ECGs and other screening evaluations. 3. Ability to provide written informed consent and complying with all study requirements and restrictions. 4. Is a non-smoker and non-tobacco user for a minimum of 6 months prior to screening Exclusion Criteria: 1. History or current evidence of any clinically significant cardiac, endocrinologic, hematologic, hepatobiliary, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator 2. Previous treatment with any GH Releasing Hormone (GHRH) analog. 3. Participation in another clinical trial or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, prior to enrollment. 4. History of cancer within the past five years (excluding non-melanoma skin cancer). 5. History of alcohol or drug abuse or dependence within 12 months of screening as determined by the Investigator. 6. Subjects with a body weight > 120 kg. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Vince and Associates Clinical Research, LLC | Overland Park | Kansas |
Lead Sponsor | Collaborator |
---|---|
Aileron Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events | 28 days | No | |
Secondary | Serum IGF-1 | Predose, Day 1-Day 28 | No | |
Secondary | Serum GH | Predose, Day 1-Day 28 | No | |
Secondary | Time to Reach Maximum Observed Plasma Concentration (Tmax) of ALRN-5281 | Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14 | No | |
Secondary | Maximum plasma concentration (Cmax) of ALRN-5281 | Predose, Day 1- 0.5,1,2,3,4,6,8,10,12,14 and 16hr post dose , Day 2-Day11 and Day14 | No | |
Secondary | Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] | AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t) | Pre Dose, Day1- 0.5,1,2,3,4,6,8,10,12,14 and 16h post dose, Day2- Day11 and Day 14 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00957671 -
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
|
Phase 4 |